Clinical Trial

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

Study acronym: VITESS
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.
Protocol Amendment History 4 changes
notable Trial sites expanded: 33 -> 52 locations 2026-07-09
notable Trial sites expanded: 28 -> 33 locations 2026-06-23
notable Trial sites expanded: 15 -> 18 locations 2026-05-06
notable Trial sites expanded: 10 -> 13 locations 2026-04-25
Trial Details
NCT Number NCT07431177
Lead Sponsor Novartis Pharmaceuticals
Conditions Non-segmental Vitiligo
Enrollment 210 participants
Start Date 2026-03-09
Primary Completion 2028-06-06 (estimated)
Study Completion 2030-01-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-08